论文部分内容阅读
随着“十二五”国家中药产业规划的出台,中医药发展作为完善基本医疗卫生制度的六项重点任务之一已被单项列出,在各部门出台的政策措施中,包含了一系列符合中医药特点、有利于中医药优势特色发挥的政策措施,国家对于民生保健和新药研发的投入明显増加,这为中药产业发展提供了重要的基本条件,中药产业面临着前所未有的发展机遇。从全球角度看,人工合成的小分子药物研制已进入明显的制约瓶颈,经FDA批准进入临床或批准上市的小分子药物数量逐年减少,
With the promulgation of the “Twelfth Five-Year Plan” national TCM industry plan, the development of Chinese medicine as one of the six key tasks for improving the basic medical and health system has been listed separately. Among the policy measures promulgated by various departments, one Series of traditional Chinese medicine in line with characteristics that are conducive to the advantages and characteristics of traditional Chinese medicine to play a policy measures, the state for people's livelihood health and new drug research and development investment increased significantly, which provides an important basic conditions for the development of Chinese medicine industry, Chinese medicine industry is facing unprecedented opportunities for development. From a global perspective, the development of synthetic small molecule drugs has entered a clear bottleneck constraints, the FDA approved the clinical or approved the listing of small molecule drugs decreased year by year,